Tandem Diabetes Care Inc Dossier - Source-backed chat

Tandem Diabetes Care Inc

TNDMNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.37

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $16.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.1B

Enterprise Value $1.7B

Shares Outstanding 68.3M diluted

Moat Rating None

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Tandem Diabetes Care is navigating a transitional phase in 2026, characterized by its shift to a Pay-As-You-Go (Pay/Go) commercial model and expansion into the pharmacy channel. While these transitions create short-term headwinds for recognized revenue and gross margins, they lay the foundation for highly predictable, recurring, and profitable cash flows starting in 2027. Differentiated product momentum from the Tandem Mobi system, expanding integration with next-generation CGMs (such as Dexcom G7), and upcoming pipeline milestones (including the Mobi Tubeless pump) position the company to capture significant share in an underpenetrated global automated insulin delivery (AID) market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets20 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$28.70

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$18.00

Intense competitive pressure from Insulet's Omnipod 5 and Medtronic's integrated AID systems leads to market share erosion in tech-forward and pediatric cohorts. The Pay/Go transition causes prolonged revenue recognition delays and deeper-than-expected gross margin compression. Regulatory delays for the Mobi Tubeless pump push commercialization timelines into late 2027, delaying the path to profitability.

Base CaseCentral scenario

$28.70

Matches the consensus mean

Tandem successfully delivers on its reaffirmed FY 2026 guidance of $1.065 billion to $1.085 billion in sales, supported by steady international expansion and stable U.S. pump shipments. Gross margins improve to the guided 56%-57% range, and the company achieves positive adjusted EBITDA of 5%-6%. The transition to the Pay/Go model progresses smoothly, setting up accelerated, predictable revenue growth and full profitability in FY 2027.

Bull CaseUpside scenario

$50.00

Rapid adoption of the Tandem Mobi system and accelerated clearance of the Mobi Tubeless pump drive double-digit shipment growth. The Pay/Go transition completes faster than expected, minimizing near-term revenue drag. High-margin recurring supply sales shift rapidly to the pharmacy channel, driving gross margins above 58% and accelerating profitability by late 2026.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong product portfolio featuring the compact Tandem Mobi system and t:slim X2, both utilizing advanced Control-IQ hybrid closed-loop technology.
Strategic commercial shift toward a Pay/Go model and pharmacy channel distribution, which will drive highly predictable, recurring revenue and superior long-term margins.
Robust balance sheet with $570.26 million in cash and short-term investments as of Q1 2026, providing ample runway to fund R&D and commercial initiatives.
Expanding addressable market with recent CE Mark approvals for Type 2 diabetes and Type 1 diabetes during pregnancy, opening new high-growth patient cohorts.

Key Investment Risks

Near-term financial volatility and margin compression associated with the transition to the Pay/Go commercial model.
Intense competition in the automated insulin delivery (AID) space from established players like Insulet (Omnipod) and Medtronic.
High dependency on continuous glucose monitoring (CGM) partner integrations and compatibility (e.g., Dexcom, Abbott) to maintain system efficacy.
Regulatory risks associated with the timely submission, review, and clearance of pipeline products such as the Mobi Tubeless pump.

Thesis Invalidation Triggers

Failure to submit the Mobi Tubeless 510(k) application or significant regulatory delays from the FDA.
A material downward revision of the FY 2026 sales guidance ($1.065B - $1.085B) indicating severe adoption friction.
Gross margins falling consistently below 55%, signaling that Pay/Go headwinds or manufacturing inefficiencies are worse than modeled.
Significant loss of market share in key pediatric or tech-forward cohorts to competitors' tubeless or integrated offerings.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.